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Objectives The primary objective was to determine if wireless remote monitoring with automatic clinician alerts reduces the
time from a clinical event to a clinical decision in response to arrhythmias, cardiovascular (CV) disease progres-
sion, and device issues compared to patients receiving standard in-office care. A secondary objective was to
compare the rates of CV health care utilization between patients in the remote and in-office arms.
Background In addition to providing life-saving therapy, implantable cardioverter-defibrillators collect advanced diagnostics
on the progression of the patient’s heart disease. Device technology has progressed to allow wireless remote
monitoring with automatic clinician alerts to replace some scheduled in-office visits.
Methods The CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) study was a multi-
center, prospective, randomized evaluation involving 1,997 patients from 136 clinical sites who underwent inser-
tion of an implantable cardioverter-defibrillator (including cardiac resynchronization therapy devices) and were
followed up for 15 months. Health care utilization data included all CV-related hospitalizations, emergency de-
partment visits, and clinic office visits.
Results The median time from clinical event to clinical decision per patient was reduced from 22 days in the in-office
arm to 4.6 days in the remote arm (p  0.001). The health care utilization data revealed a decrease in mean
length of stay per CV hospitalization visit from 4.0 days in the in-office arm to 3.3 days in the remote arm
(p  0.002).
Conclusions Wireless remote monitoring with automatic clinician alerts as compared with standard in-office follow-up signifi-
cantly reduced the time to a clinical decision in response to clinical events and was associated with a significant
reduction in mean length of CV hospital stay. (Clinical Evaluation of Remote Notification to Reduce Time to
Clinical Decision [CONNECT]; NCT00402246) (J Am Coll Cardiol 2011;57:1181–9) © 2011 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.12.012Implantable cardioverter-defibrillators (ICDs) and cardiac
resynchronization therapy with defibrillation (CRT-D)
have been shown to improve survival beyond that afforded
by optimized drug therapy (1–3). Since the acceptance of
indications for primary prevention of sudden cardiac death
(1,3,4), the numbers of defibrillator implantations have
increased. In 2007, an estimated 1 million cardiac devices
were implanted, with at least 4 million annual follow-up
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follow-up is an in-person evaluation 1 month after implant,
again 2 months later, and every 3 to 6 months thereafter (6).
This volume of visits adds burden to clinicians and creates
the need for a more cost-effective solution for the follow-up
of these patients.
Defibrillators have evolved so that they not only deliver
life-saving therapy for ventricular arrhythmias, but also
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formation pertaining to the func-
tion of the ICD and the clinical
status of the patient, such as the
number of shocks delivered and
atrial arrhythmias.
Patients with defibrillators are
at high risk for atrial fibrillation
(AF) and atrial flutter, which pre-
dispose them to embolic events
and worsening of congestive heart
failure (7–10). Atrial arrhythmias
can also cause inappropriate
shocks (11,12). The accuracy of
atrial arrhythmia detection has
been established (13,14). Rapid
awareness of AF is important in
that practice guidelines allow for cardioversion of AF
without the need for a transesophageal echocardiogram
procedure or anticoagulation therapy during the first 48 h
after onset (15). Clinical events including AF events can
trigger an auditory signal to the patient. However, a
limitation of this alerting approach is that decreased audi-
tory acuity of elderly patients may lead to under-recognition
of that signal (16).
Defibrillators now have remote monitoring capabilities
that allow clinicians to have remote access to the complete
device diagnostic information. In response to clinician
request or a predefined schedule, patients transmit diagnos-
tic information from the device to a central server through
standard phone lines by holding a wand physically con-
nected to a home monitor. Clinicians can access the patient
transmitted diagnostics through a secure Internet interface.
Remote monitoring has been shown to be easy to use for
patients and comparable to in-office device interrogations
(17). It has also been demonstrated to be efficient (5). In
addition, the PREFER (Pacemaker Remote Follow-Up
Evaluation and Review) study showed that remote moni-
toring in pacemakers led to quicker and more frequent
detection of clinical events than standard of care (18). The
latest defibrillators have wireless technology that can auto-
matically transmit data from a patient’s defibrillator to the
home monitor and central server without any patient action.
The transmissions include regularly scheduled checks and
automatic clinician alerts in response to clinical events.
The purpose of the CONNECT (Clinical Evaluation of
Remote Notification to Reduce Time to Clinical Decision)
study is to determine the impact of wireless remote moni-
toring with automatic clinician alerts on the time from
clinical events to clinical decisions and on health care
utilization.
Methods
Study design. The CONNECT study was a multicenter,
Abbreviations
and Acronyms
AF  atrial fibrillation
AT  atrial tachycardia
CRT-D  cardiac
resynchronization
therapy-defibrillator
CV  cardiovascular
ED  emergency
department
HCU  health care
utilization
ICD  implantable
cardioverter-defibrillator
LOS  length of stayprospective, randomized evaluation of wireless remote mon- 1itoring in a population of 1,997 adult patients implanted
with a Medtronic (Minneapolis, Minnesota) wireless ICD
or CRT-D system utilizing the Medtronic CareLink Net-
work. Institutional review boards approved the protocol at
all 136 participating U.S. centers. Details of the study
design were previously reported (19). In summary, the study
was designed to evaluate the impact of remote monitoring
with automatic clinician alerts (wireless remote monitoring)
on how quickly clinicians became aware of a clinical event
and formulated a corresponding clinical decision regarding a
plan of action. Over a 15-month period, the effect of
wireless remote monitoring was compared directly with
standard in-office device follow-up. Patients were enrolled
after signing an informed consent form and an authoriza-
tion to use and disclose health information. After successful
insertion of an ICD or CRT-D, patients were randomly
assigned in a 1:1 manner, stratified by device type, to
wireless remote monitoring or in-office care. Inclusion
criteria included: 1) being able and willing to replace
regularly scheduled in-office follow-ups with remote follow-
ups; and 2) being able to attend all required follow-up visits.
Patients were excluded for: 1) permanent AF (constant AF
for which there were no plans to attempt to restore sinus
rhythm); 2) chronic warfarin therapy; 3) having had a
previous ICD, CRT device, or pacemaker; 4) being 18
ears of age; and 5) having a life expectancy 15 months.
bjectives. The primary objective was to determine if
ireless remote monitoring with automatic clinician alerts
educes the time from a clinical event to a clinical decision
n response to arrhythmias, cardiovascular (CV) disease
rogression, and device issues compared to patients receiv-
ng standard in-office care.
The primary outcome, time to clinical decision, is defined
s the time from device detection of a clinical event to a
ecision being made in response to the event, as reported by
he clinician or as evidenced by device data obtained at
nterrogation. Clinical events are defined in Table 1. The
efinitions of events were applied equally to both arms
egardless of whether an automatic clinician or audible
atient alert occurred.
The key secondary objective was to compare cardiovas-
ular health care utilization (HCU) rates between arms for
ach HCU type (hospitalizations, emergency department
ED], and unscheduled clinic office/urgent care visits).
ength of hospital stay (LOS) and actions taken at each
CU event were also compared between arms.
rogramming. Tachycardia and bradycardia therapy and
etection programming was left to the clinician’s discretion.
rogramming related to the defibrillator, lead, and clinical
anagement alerts were controlled (Table 1). To limit the
umber of device transmissions sent in the remote arm, a
onservative approach was taken when selecting alert
hresholds. Only values warranting clinician attention and
ossible intervention were specified. Specifically, the atrial
achycardia (AT)/AF burden threshold was programmed to
2 h/day, and the rapid ventricular rate during AT/AF alert
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March 8, 2011:1181–9 Remote Monitoring of ICD Patientswas programmed to 120 beats/min for 6 h/day. Exactly 1
automatic clinician alert can be sent for any 1 clinical event
between in-office device interrogations.
IN-OFFICE ARM. Only audible patient alerts associated with
lead and device integrity were enabled for patients in the
in-office arm (Table 1) because they are nominal settings
and considered standard of care.
REMOTE ARM. All automatic clinician alerts were enabled
or patients in the remote arm. Audible patient alerts were
isabled with the exception of those related to lead and
evice integrity (Table 1).
ollow-up. All patients had study visits at 1, 3, 6, 9, 12, and
5 months post-implant. Patients in the remote arm received
home monitor, and their in-office visits at 3, 6, 9, and 12
onths were replaced with remote visits, including a remote
evice transmission. Clinicians had access to the entire set of
evice-collected diagnostics for all study patients.
tatistical analysis. An intent-to-treat analysis served as
he primary analysis for all objectives. An -level of 0.05
was employed for each analysis. Poolability assessments
were performed to ensure that the effect of wireless remote
monitoring did not vary by device type.
The primary objective analysis included all analysis cohort
patients who experienced at least 1 clinical event. Event
onset was defined as the time when criteria for triggering an
alert were met. The time between event onset and clinical
decision was calculated for each event a patient experienced.
The average time from event onset to clinical decision was
determined for each patient so that each patient contributed
1 value to the analysis. If a patient experienced multiple
events of a specific type (e.g., 12 h AT/AF burden in a
day) between 2 consecutive evaluations, only the first of
these was paired with the next device interrogation/visit and
counted toward the analysis. The thought was that the onset
of a specific event type is clinically meaningful and, left
undetected by a clinician, it may persist (e.g., develop into
chronic AF) until treated. In cases in which a subject
experiences 24 h of AT/AF for 30 consecutive days until it
Protocol Required Alert Programming (Clinical Events)Table 1 Protocol Required Alert Programming (Clinical Events)
Alert/Clinical Event Rem
Medtronic CareLink Home Monitor Yes
Clinical management alerts
AT/AF daily burden Automatic clinician alert (12 h/
Ventricular rate during AT/AF Automatic clinician alert (120 b
Number of shocks delivered Automatic clinician alert (2 sho
All therapies exhausted in a zone Automatic clinician alert (on)
Lead/device integrity alerts
Lead impedance out of range Automatic clinician alert  aud
VF detection/therapy off Automatic clinician alert  aud
Low battery voltage RRT Automatic clinician alert  aud
Excessive charge time EOS Automatic clinician alert  aud
AT/AF  atrial tachycardia/atrial fibrillation; EOS  end of service; RRT  recommended replaceis reported to a clinician, the authors did not believe thatshould constitute 30 unique events, as it is most likely 1 long
AT/AF episode. However, defining the analysis cohort this
way meant that if in-office subjects have 5 days over a 30-day
period in which they experienced 12 to 24 h of AT/AF, only
the first would count toward the analysis, whereas had the
subject been in the remote arm, this might have resulted in 5
alerts and a shorter average time to decision.
A sensitivity analysis including all events was also
performed. A Wilcoxon rank-sum test was used to
compare the median time from event onset to clinical
decision between treatment arms. All events from the day
after randomization to patient exit/death were included,
except AT/AF burden and ventricular rate during AT/AF
events that occurred in patients after the physician had
terminated a rhythm control strategy.
To allow for multiple HCU events per patient, an
Andersen-Gill proportional hazards regression model was
used to compare the hazard rates for each type of HCU
event (hospitalization, ED, unscheduled office/urgent visit)
between arms (20). All patients in the analysis cohort were
included in this analysis, which was stratified by device type.
A negative binomial model accounting for device type was
fit to compare the LOS between arms (21).
A mixed model was fit with randomization arm and
device type as predictors and a compound symmetry corre-
lation structure to compare average cost for CV hospital-
izations between arms. Because detailed economic data were
not collected, national cost estimates for CV hospitalization
based on data from the Medicare Limited Data Set Stan-
dard Analytic Files for 2002 to 2007 were assigned to each
visit depending on LOS and whether the visit was deemed
inpatient or outpatient. Based on Medicare rules, a patient
can be hospitalized up to 3 days and still be considered
outpatient. Hospitalizations of 3 days or less were assigned
inpatient/outpatient status and the corresponding national
cost estimate using Bernoulli distributions with pre-
specified probabilities depending on LOS (probability of
being an inpatient visit for 1, 2, and 3 days is 70%, 89%,
and 98%, respectively). A 95% 2-sided bootstrap confi-
m In-Office Arm
No (not provided)
Off
in for 6 h AT/AF per day) Off
Off
Off
tient alert (nominal ranges) Audible patient alert (nominal ranges)
tient alert (nominal ranges) Audible patient alert (nominal ranges)
tient alert (nominal ranges) Audible patient alert (nominal ranges)
tient alert (nominal ranges) Audible patient alert (nominal ranges)
ime; VF  ventricular fibrillation.ote Ar
day)
eats/m
cks)
ible pa
ible pa
ible pa
ible padence interval was generated for the difference (remote
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Remote Monitoring of ICD Patients March 8, 2011:1181–9minus in-office) in mean cost per visit using 10,000
simulations in which inpatient/outpatient status was
assigned and a model fit for each simulation. Bootstrap-
ping was similarly used to estimate mean cost per
hospitalization visit in each arm.
Results
Study timelines and demographics. Patients were en-
rolled from November 2006 through May 2008. The last
follow-up visit occurred in August 2009. There were
1,997 patients enrolled from 136 centers. There were
1,014 patients randomly assigned to the remote arm and
983 patients randomly allocated to the in-office arm. The
remote and in-office arm patients had similar demographic
Baseline DemographicsTable 2 Baseline Demographics
Remote
(n  1,014)
In-Office
(n  983)
Total
(n  1,997)
Sex, male 70.5% 71.7% 71.1%
Age, yrs 65.2 12.4 64.9 11.9 65.0 12.1
LVEF, % 28.6 10.0 29.2 10.3 28.9 10.2
NYHA functional classification
No heart failure 5.3% 6.7% 6.0%
Class I 3.9% 4.7% 4.3%
Class II 40.9% 39.5% 40.2%
Class III 48.5% 47.5% 48.0%
Class IV 1.5% 1.5% 1.5%
Cardiovascular history
Cardiomyopathy 96.1% 95.3% 95.7%
Ischemic 63.3% 61.5% 62.4%
Nonischemic 32.0% 33.5% 32.7%
Hypertrophic 1.8% 1.5% 1.7%
Dilated 28.0% 29.8% 28.9%
Hypertension 74.2% 76.9% 75.5%
Cerebrovascular accident 8.1% 7.3% 7.7%
Diabetes mellitus 34.8% 38.0% 36.4%
Atrial fibrillation 14.9% 13.3% 14.1%
Sustained monomorphic VT 6.5% 6.5% 6.5%
Sustained polymorphic VT 1.3% 1.9% 1.6%
Values are % or mean  SD.
LVEF  left ventricular ejection fraction; NYHA  New York Heart Association; VT  ventricular
tachycardia.
Summary of Time to Decision by Alert Event TypeTable 3 Summary of Time to Decision by Alert Event Type
Device Event
AT/AF burden at least 12 h
Ventricular rate during AT/AF 120 beats/min during at least 6 h AT/AF
At least 2 shocks delivered in an episode
Lead impedances out of range
All therapies in a zone exhausted for an episode
VF detection/therapy off
Low battery
TotalAbbreviations as in Table 1.data (Table 2). Of all enrolled patients, 1,980 met inclusion/
exclusion criteria and make up the analysis cohort (remote
arm  1,005; in-office arm  975). Seventeen randomized
patients were excluded from the analysis cohort for the
following reasons: permanent AF (n  2), not implanted
with a required study device (n  9), previous defibrillator
or pacemaker (n  3), unwillingness to conduct CareLink
follow-up visits (n  2), and inability to attend all required
follow-up visits (n  1).
Primary objective. There were 317 patients with at least 1
clinical event, 172 (17%) in the remote arm and 145 (15%)
in the in-office arm. A total of 966 clinical events occurred
in those patients, with AT/AF burden (74%, n  717) and
ventricular rate during AT/AF (9%, n 88) being the most
frequent (Table 3). The median time from an event occur-
ring to a clinical decision per patient was 4.6 days in the
remote arm and 22 days in the in-office arm (Fig. 1). This
resulted in a significant reduction from the time an event
occurs to a clinical decision (p 0.001), observed to be 17.4
days (79%). A sensitivity analysis including multiple events
of the same type between an event onset and a device
interrogation/visit also yielded a significant reduction (p 
0.001).
Automatic clinician alert transmissions. In the remote
arm, there were 575 clinical events, and 329 of these events
triggered an automatic clinician alert. There were 246
clinical events that did not trigger an automatic clinician
alert because the alert was programmed off (7%) or the alert
was not reset after being previously triggered (93%). For
example, if an alert triggers for an AT/AF burden event,
it will not trigger again until reset during an in-office
interrogation. When an automatic clinician alert was
triggered, 180 (55%) resulted in a successful transmission
to the CareLink network. Automatic clinician alerts were
triggered but not successfully transmitted for 149 (45%)
clinical events, mainly because the home monitor was not
set up and initiated to send out transmissions. Other
reasons included circumstances where the patient was not
home, or the monitor was unplugged or not connected to
a phone line.
. of Events (No. of Patients)
No. of Days From Event Onset
to Clinical Decision
Median (Interquartile Range)
mote In-Office Remote In-Office
(107) 280 (105) 3 (1–15) 24 (7–57)
(26) 47 (37) 4 (2–13) 23 (5–40)
(35) 32 (23) 0 (0–1.5) 0 (0–2)
(18) 12 (6) 0 (0–9) 17 (5.5–45)
(12) 11 (6) 0 (0–1) 9 (0–36)
(10) 8 (8) 0 0 (0–84)
(1) 1 (1) 30 0
(172) 391 (145) 3 (0–13) 20 (4–52)No
Re
437
41
44
26
16
10
1
575
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March 8, 2011:1181–9 Remote Monitoring of ICD PatientsThe timing of automatic clinician alerts in the clinical
decision-making process could only be assessed for events
that were successfully transmitted and used to make a
clinical decision. Of the 180 successfully transmitted events,
40 were not viewed before clinical decision. For the remain-
ing 140 events, the time from when an automatic clinician
alert was triggered to when the transmitted information was
viewed was 1.5 days in 70% of the cases. When time to
linical decision for these events was longer (e.g., 2 days)
the majority of time fell between first viewing the alert and
reporting a decision.
Automatic clinician alerts were classified by the clinician
as “meaningful” 62% of the time and “timed appropriately”
84% of the time. Conversely, for 12% of automatic clinician
alerts, clinicians thought “it could have waited longer,” and
for only 2%, clinicians “didn’t want to know at all.” At each
routine in-office device check, clinicians were asked if “new
and meaningful information” was obtained by the device
interrogation: they reported “yes” for only 24% of the visits.
Health care utilization. There were 6,227 cardiovascular-
related HCU visits. There was no statistical difference in the
rates of any of the HCU types (Fig. 2), or in the rates of
transesophageal echocardiograms (p  0.67) between the 2
arms.
The mean LOS during a CV hospitalization was signif-
icantly reduced (18%, p 0.002) in the remote arm (Fig. 3)
after controlling for LOS differences between device types.
The estimated mean LOS per hospitalization was 3.3 days
in the remote arm and 4.0 days in the in-office arm. Among
Figure 1 Distribution of Time From Clinical Event to Decision p
Box-and-whisker plots show the quartiles with the medians labeled, and the whiskpatients with a clinical event during follow-up, those in theremote arm had a significantly shorter mean LOS per
hospitalization compared with in-office arm patients (3.2 vs.
4.3 days, p  0.007) (Fig. 4).
Given that routine clinic visits were replaced by wireless
remote monitoring in the remote arm, the observed rate of
total clinic visits per patient year was higher in the in-office arm
(6.3) than in the remote arm (3.9). The annualized rates of
many of the specific actions taken at both scheduled and
nonscheduled HCU visits were similar between the 2 arms
(Fig. 5).
Mortality rates between arms were compared using the
log-rank test and were not significantly different for ICD
patients (p  0.31) or CRT-D patients (p  0.46).
Health care economics. As a result of the shorter hospital
LOS for the remote arm as compared with the in-office
arm, the estimated mean cost per hospitalization was
significantly lower. A hospitalization in the remote arm was
estimated at $8,114 compared with $9,822 for the in-office
arm. After accounting for the impact of device type on cost,
the mean difference between arms was estimated to be
$1,793 (95% confidence interval: $1,644 to $1,940).
Discussion
This study demonstrated that wireless remote monitoring
allows clinicians to make clinical decisions 17.4 days sooner
when compared to the in-office arm. Remote arm patients
with AT/AF events had a reduced median time from arrhyth-
tient
tend to the fifth and 95th percentiles.er Pa
ers exmia onset to a responsive clinical action (3 days vs. 24 days).
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Remote Monitoring of ICD Patients March 8, 2011:1181–9Without wireless remote monitoring, AT/AF would only be
detected at routine clinic visits or unscheduled visits related to
symptoms, embolic events, or worsening heart failure. Other
recent studies have also demonstrated positive benefits associ-
ated with remote monitoring (22,23).
Automatic clinician alerts were determined by clinicians
to be meaningful and timely in 62% and 84% of cases,
respectively. In contrast, only 24% of routine in-office device
follow-ups provided new and meaningful information.
Clinics often have a large infrastructure in place at signifi-
cant expense to follow up patients with devices. Because a
substantial number of scheduled in-office visits did not
result in new and meaningful information, the impact of
such an infrastructure on patient outcomes may be dimin-
ished. Findings from this study suggest that wireless remote
monitoring with automatic clinician alerts may be a viable
substitute for in-office visits.
No statistical difference was found between the remote
arm and in-office arm for rates of mortality, CV clinic visits,
ED visits, and hospitalizations, despite each alert having to
be reset by interrogation. However, the observed rate of
total clinic visits per patient-year was 2 days higher in the
in-office arm (6.3) as compared with the remote arm (3.9).
The time spent conducting remote device follow-ups would
offset the in-office visits saved to some degree, but a precise
Figure 2 Annualized Rate of Cardiovascular Health Care Utiliza
Annualized rate of cardiovascular health care utilization visits per patient-year by a
a trend toward more unscheduled clinic visits, many of which were due to the nee
arm; blue bars indicate in-office arm. ED  emergency department.calculation cannot be made as those data were not collected.Remote arm patients experienced a significant reduction
in the mean LOS for hospitalizations (3.3 days vs. 4.0 days),
resulting in a lower cost, estimated to be $1,793. One
explanation is that wireless remote monitoring, which af-
forded faster clinical decision making, could have a positive
impact on patients’ health. However, determination of the
exact mechanism will require further investigation.
The effectiveness of a wireless remote monitoring
system requires the attention of the patient and clinician.
The patients must activate an initial monitor setup. In
addition, patients who are away from their monitor for
extended periods of time reduce the ability of automatic
clinician alerts to transmit. Once the system was activated,
a successful transmission led to a clinician viewing the data
within 1.5 days 70% of the time. When the time to clinical
decision for such events was at least 2 days, the majority of time
was attributed to the time from first viewing the alert by a
clinician to when a clinical decision was made. The wide range
of days from event onset until clinical decision (interquartile
range: 0 to 13 days) reveals that not all clinicians managing
patients in the remote arm responded rapidly to automatic
clinician alerts. In addition, many clinical events did not trigger
automatic clinician alerts because it was not reset after the first
occurrence in response to an event. Better deployment and
utilization of the wireless remote monitoring system can result
isits per Patient-Year by Arm
d p values from Anderson-Gill proportional hazards regression model. There was
he patient to come to the office to reset the alerts. Green bars indicate remotetion V
rm, an
d for tin more timely treatment decisions.
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March 8, 2011:1181–9 Remote Monitoring of ICD PatientsStudy limitations. Although the study was designed to
compare HCU rates, events were not adjudicated to verify
relatedness to specific disease states. Only adverse events that
Figure 3 Mean LOS per Hospitalization Visit by Arm and Device
Estimated mean length of stay (LOS) per cardiovascular hospitalization by arm and
blue bars indicate in-office arm. CRT-D  cardiac resynchronization therapy-defibril
Figure 4 Mean Length of Stay per Hospitalization by Arm and W
Estimated mean length of stay per cardiovascular hospitalization determined by us
Green bars indicate remote arm; blue bars indicate in-office arm.resulted in a HCU were collected. Detailed cost data and status
(inpatient vs. outpatient) were not collected for hospitaliza-
tions, necessitating cost estimations. The observed benefit of
up
e type using a negative binomial model. Green bars indicate remote arm;
CD  implantable cardioverter-defibrillator.
er Patient Had a Clinical Event
negative binomial model.Gro
devic
lator; Iheth
e of a
1188 Crossley et al. JACC Vol. 57, No. 10, 2011
Remote Monitoring of ICD Patients March 8, 2011:1181–9the wireless remote monitoring system was constrained owing
to an initial delay in monitors being activated in patient’s
homes and clinicians not resetting automatic clinician alerts.
Conclusions
Wireless remote monitoring with automatic clinician alerts
as compared with standard in-office follow-up significantly
reduced the time to a clinical decision in response to clinical
events and was associated with a significant reduction in
mean length of hospital stay. Clinics employing wireless
remote monitoring may expect fewer total clinic visits per
year while not increasing the rate of ED visits or cardiovas-
cular hospitalizations for their patients.
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